Quick Dispatch:
Your semaglutide soul SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your semaglutide soul SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients ships.
Need Help?
Questions about semaglutide soul SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for semaglutide soul SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients in your area.
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
26.92
Results of SOUL Trial with Oral Semaglutide
24.29
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
29.03
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
22.71
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
25.47
Oral formulation of semaglutide lowered the risk of major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo. ✓ SOUL study #ACC25 #ACC2025 #CardioX #
21.33
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
26.99
